Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials

被引:5
|
作者
Neurath, Laura [1 ,2 ]
D'Amico, Ferdinando [1 ,2 ,3 ]
Danese, Silvio [1 ,2 ,4 ,5 ]
机构
[1] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
[4] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Via Olgettina 60, Milan, Italy
[5] Univ Vita Salute San Raffaele, Via Olgettina 60, Milan, Italy
关键词
Inflammatory bowel disease; ulcerative colitis; treatment; phase II and phase III trials; INFLAMMATORY-BOWEL-DISEASE; JANUS KINASE INHIBITOR; TO-SEVERE; MAINTENANCE THERAPY; CROHNS-DISEASE; DOUBLE-BLIND; BIOLOGICAL THERAPY; INDUCTION THERAPY; ANTI-TNF; VEDOLIZUMAB;
D O I
10.1080/14728214.2023.2186399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionCurrent therapeutic options for patients with ulcerative colitis comprise monoclonal antibodies against tumor necrosis factor (TNF), alpha4/beta7 integrin, and interleukin (IL)12/23 as well as small molecules such as tofacitinib, upadacitinib, ozanimod, and filgotinib. However, many patients fail to respond to these agents or have loss of response over time. Therefore, there is a large unmet clinical need for new therapeutic agents.Areas coveredHere, we review recent phase 2/3 studies in active ulcerative colitis and discuss preliminary data on the efficacy (clinical, endoscopic, and histologic remission) and safety of novel drugs including Janus kinase (JAK) inhibitors, IL23 blockers, integrin inhibitors, and S1P1R modulators.Expert opinionWe highlight the potential impact of these agents for the future therapeutic landscape of this disease with special emphasis on clinical impact, unmet needs, safety aspects, and advanced combination therapy.
引用
收藏
页码:27 / 42
页数:16
相关论文
共 50 条
  • [1] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    [J]. PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [2] A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis
    Law, Cindy C. Y.
    Kayal, Maia
    Mehandru, Saurabh
    Colombel, Jean-Frederic
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 17 (02) : 109 - 117
  • [3] A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
    Aoun, Roni
    Hanauer, Stephen
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (05) : 411 - 423
  • [4] Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
    Tremblay, Douglas
    Hoffman, Ronald
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2021, 26 (04) : 351 - 362
  • [5] Emerging drugs for the treatment of glaucoma: a review of phase II & III trials
    Kaplan, Tyler M.
    Sit, Arthur J.
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 321 - 331
  • [6] Cost Per Clinical Outcomes With Biologics for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Jansen, Jeroen P.
    Mody, Reema
    Patel, Haridarshan
    Lorenzi, Maria
    Ursan, Iulia
    Alberton, Mark
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1 - S2
  • [7] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [8] Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis
    Jansen, J.
    Mody, R.
    Ursan, I.
    Lorenzi, M.
    Patel, H.
    Alberton, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S239 - S240
  • [9] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [10] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Lazar, Andreas
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115